1 The EIC Accelerator Project

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups with high-risk, high-potential innovations. This program primarily targets deep tech companies and aims to enhance their capacity to scale and access private funding. It provides tailored funding options that include grants and equity, which are instrumental in fostering innovation and commercial success.

Funding Structure

The EIC Accelerator provides a dual funding mechanism:

Purpose and Impact

The EIC Accelerator plays a crucial role in the European deep tech and startup ecosystem by providing essential financial support that enables companies to bring groundbreaking innovations to market. It addresses a critical gap in funding and assists companies in scaling their operations effectively. By improving access to private investment, the EIC Accelerator empowers startups to attract venture capital and other private funding sources, thereby enhancing their overall viability and competitiveness.

Case Study: GenetikaPlus Ltd and the RxMine Project

Company Overview: GenetikaPlus Ltd is an innovative Israeli startup that has made significant strides in the field of personalized medicine, particularly in mental health treatment. The company aims to revolutionize the way depression is treated by utilizing genetic insights.

Project Overview: The EIC Accelerator project titled RxMine is a pioneering initiative that focuses on developing a simple blood test designed to identify the most effective treatment options for patients suffering from depression. This project was submitted as a Step 2 proposal on March 23, 2022, and successfully won funding after advancing to the Step 3 interview stage.

Technology Background

The RxMine project leverages advanced genetic testing technologies to analyze a patient's genetic makeup, enabling healthcare providers to tailor antidepressant treatment effectively. This approach is rooted in the understanding that individuals respond differently to various medications due to their unique genetic profiles.

Core Technology: The blood test developed by GenetikaPlus utilizes genomic data to identify specific biomarkers associated with treatment efficacy and side effects. This information allows clinicians to make informed decisions regarding medication prescriptions, thereby enhancing treatment outcomes and minimizing trial-and-error approaches that can prolong patient suffering.

Scientific Context: Traditional methods of treating depression often involve a lengthy process of prescribing and adjusting medications, which can be frustrating for both patients and healthcare providers. By implementing a genetic-based solution, RxMine aims to streamline the treatment process, reduce time to effective therapy, and improve overall patient satisfaction.

Conclusion

The EIC Accelerator program serves as a vital mechanism in bolstering the European deep tech landscape, exemplified by the success of GenetikaPlus Ltd and its RxMine project. By providing substantial funding and support, the EIC Accelerator enables innovative startups to navigate the complexities of product development, scale operations, and ultimately deliver impactful solutions to pressing societal challenges, such as mental health treatment. Through its focused funding strategies, the EIC Accelerator continues to foster a vibrant ecosystem of innovation across Europe.

2 The Funding Rounds

GenetikaPlus Ltd: Financing and Funding Activity Since EIC Accelerator Success

GenetikaPlus Ltd, headquartered in Israel and now also known as NeuroKaire, has demonstrated significant fundraising momentum since submitting its successful EIC Accelerator application on March 23, 2022. The company specializes in precision medicine for psychiatric and neurological diseases, notably through its “brain-in-a-dish” technology for optimizing antidepressant selection.

Financing Raised & Funding Rounds

• Total Funds Raised: As of July 26, 2022, GenetikaPlus had raised approximately $27.82 million across five funding rounds.
• Major Rounds Post-EIC Submission:
• EIC Accelerator Grant/Equity (July 26, 2022): GenetikaPlus was awarded up to €17.5 million (approximately $17.82M), representing a blend of grant funding and equity investment from the European Innovation Council (EIC). This round was pivotal in supporting clinical validation and market launch efforts for the company’s core platform.
• Series A Round (September 30–October 1, 2021): Prior to the EIC award but highly relevant to subsequent growth phases, GenetikaPlus secured a $10 million Series A round led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan (B Capital Group), and Michael Zeisser (FMZ Ventures). The Series A exceeded its initial target by about one-third.

Timing & Amounts of Key Funding Rounds

Date	Round	Amount	Lead Investors
Jul 26, 2022	Grant/EIC Equity	~$17.82M	European Innovation Council
Sep/Oct 2021	Series A	$10M	GreyBird Ventures (+ others)
Mar 28,2018	Incubator/Accelerator Seed	Not disclosed	Not disclosed

Earlier incubation or accelerator support is referenced but without detailed financial reporting.

Investor Information

• Key Investors:
• GreyBird Ventures – Led both early-stage funding rounds.
• Meron Capital
• Jumpspeed Ventures
• Sapir Venture Partners
• Howard Morgan (Chairman at B Capital Group)
• Michael Zeisser (FMZ Ventures; ex-Alibaba Group executive)
• The latest major financing event includes direct support from the European Commission’s EIC program.

Company Valuations & Financial Metrics

No explicit post-money valuation figures have been published in available sources for any specific round. However:

• The size of recent financings ($27.8M total; $17.82M most recently) reflects strong investor confidence.
• Revenue figures are not publicly disclosed; current focus appears to be on clinical validation rather than commercial sales.

Exit Events: IPOs or Acquisitions

As of April 30th, 2025:

• No evidence indicates that GenetikaPlus Ltd / NeuroKaire has undergone an IPO or been acquired.
• Recent press coverage highlights continued private fundraising activity as late as December 17th, 2024—a further sign that exit events have not yet occurred.

Summary Table: Major Fundraising Milestones Since March 23rd 2022

Date	Event	Amount
Jul 26 2022	EIC Grant + Equity Award	~$17.82M
Dec 17 2024	Fundraising Continues	Undisclosed

The company's robust capital base since winning the EIC Accelerator supports ongoing multi-national trials and expansion into US/EU markets.

---

Sources:

• Genetika+ Stock Price, Funding…
• Genetika+ Wins Prestigious European Funding…
• Genetika+ happily nabs $10M in series A…
• Genetika+ Raises $10M for Personalized Medicine…
• Financings for December 17 – BioWorld

3 The Press Releases

GenetikaPlus Ltd. Post-EIC Accelerator Funding Developments Genetika+ (now operating as NeuroKaire) secured European Innovation Council (EIC) Accelerator funding in mid-2022 to advance its depression drug-matching platform. The company’s patented "Brain-in-a-Dish" technology personalizes psychiatric treatment by testing over 70 antidepressants and drug combinations against patient-derived biomarkers from a simple blood draw, combined with genetic and clinical data.

Key Updates Since EIC Award

• Clinical Validation & Scale-Up: The EIC funding supported expanded clinical trials and platform scaling for large-scale deployment, including establishing a clinical lab in Boston.
• AI Partnerships: In August 2022, Genetika+ partnered with Kahn-Sagol-Maccabi (KSM) to integrate AI algorithms with real-world depression patient data, aiming to optimize treatment personalization.
• Rebranding: The company now operates under the name NeuroKaire, reflecting its focus on transforming psychiatry and neurology care through precision medicine.

Earlier Milestones

• Series A Funding: Raised $10 million in September 2021 led by GreyBird Ventures to accelerate trials and manufacturing capabilities.
• Technology Core: Their platform reduces trial-and-error prescribing by predicting optimal therapies using stem cell-derived neuronal models ("Brain-in-a-Dish").

---

Sources

• NeuroSense and Genetika+ Initiate Precision Medicine Collaboration
• Biopharma | NeuroKaire
• Genetika+ Announces $10M Series A

The provided sources do not include direct links to press releases from genetikaplus.com or their social media accounts. For official updates beyond public third-party reports (e.g., PR Newswire), refer to their current website: NeuroKaire.

4 The Technology Advancements

GenetikaPlus Ltd: Post-EIC Accelerator Funding Advancements in Precision Psychiatry Since securing EIC Accelerator funding in March 2022, GenetikaPlus (now operating as NeuroKaire) has advanced its proprietary platform for personalized psychiatry and neurology care. Below are key developments:

---

Technology Enhancements

• Multi-modal AI integration: The company’s platform now combines stem-cell-derived neurons from patient blood samples with genomic data, clinical history, and AI-driven computer vision to predict optimal treatments for depression.
• Scalability improvements: Their biobank has expanded to include hundreds of neuronal lines from depression patients, enhancing predictive accuracy for drug responses.
• Partnership-driven advancements: Collaboration with Clexio Biosciences (February 2023) enabled screening of antidepressant candidates using patient-derived neurons, validating the platform’s utility in drug development pipelines.

---

Market Demonstrations & Clinical Applications

• Depression-focused pilots: Over 200 neuronal lines from diagnosed patients have been characterized longitudinally, demonstrating real-world applicability in predicting treatment efficacy and side effects.
• Clinical partnerships: The "Brain-in-a-Dish" technology is actively used by physicians to personalize antidepressant selection, reducing trial-and-error prescribing.

---

Intellectual Property & Research Outputs

While no new patents directly attributed to GenetikaPlus were identified post-March 2022, their core technology relies on Nobel Prize-winning iPSC methods combined with proprietary biomarker analysis frameworks described in earlier IP filings. Publicly disclosed scientific studies remain limited; however, their participation in Horizon Europe underscores ongoing R&D efforts supported by EU funding.

---

Sources

• Transforming Psychiatry and Neurology Care | NeuroKaire
• Clexio Partnership Announcement
• Horizon Europe Funding Report

+ PMWC Exhibitor Profile

5 The Partnerships and Customers

GenetikaPlus Ltd Partnerships and Strategic Positioning Post-EIC Accelerator Funding Following its 2022 EIC Accelerator win, GenetikaPlus Ltd (now operating as NeuroKaire) has solidified key partnerships and advanced its precision medicine platform for neuropsychiatric disorders. The company’s collaborations focus on enhancing drug development pipelines and commercializing biomarker-driven diagnostics.

Key Partnerships and Customers

• Pharmaceutical Collaborations: Genetika+ has partnered with undisclosed pharmaceutical companies to analyze patient-derived neuronal responses, aiding in target identification and patient stratification for clinical trials. A specific collaboration with NeuroSense was initiated in April 2024 to integrate precision medicine into NeuroSense’s Phase 2 Alzheimer’s disease trial.
• Sheba Medical Center: Listed as a customer, Sheba leverages Genetika+’s tools for personalized treatment optimization in psychiatry.

New Relationships and Market Impact

The NeuroSense partnership exemplifies how Genetika+ positions itself as a biomarker innovator, enabling pharma partners to incorporate companion diagnostics into clinical trials. By providing mechanistic insights from patient-derived neurons, the company enhances clinical trial success rates while differentiating its offerings in the competitive AI-driven drug discovery space.

Technological Advancements Through Partnerships

Collaborations facilitate access to large-scale clinical datasets, which refine Genetika+’s multi-modal AI platform combining stem-cell biology, genomics, and computer vision. These relationships directly support scaling efforts by validating their technology across diverse patient populations and therapeutic areas like depression and Alzheimer’s disease.

---

Sources

• NeuroSense Collaboration Announcement
• Customer Profile (CB Insights)
• EIC Funding Press Release
• Technology Overview

6 The Hiring and Company Growth

NeuroKaire (formerly GenetikaPlus): Team Growth and Scaling Since EIC Accelerator Funding NeuroKaire, an Israeli precision medicine company focused on optimizing psychiatric treatments through personalized drug selection, has positioned itself as a leader in mental health innovation. While specific headcount figures remain undisclosed, the company’s leadership structure includes key roles such as CEO Talia Cohen Solal (co-founder), CSO Daphna Laifenfeld (co-founder), COO Elad Bibi Aviv, and CPO Issar Yazbin. Additional critical hires include Gosia Jaremko (Chief Laboratory Officer), David Pattison (Business Development Director), and Orit Goldman (VP of Stem Cell Product), reflecting strategic investments in laboratory operations, commercialization, and therapeutic R&D.

Recent team expansions align with NeuroKaire’s focus on scaling its platform for depression treatment optimization. The inclusion of stem cell specialists and laboratory experts suggests bolstered capabilities in biomarker discovery and drug-response prediction technologies. While no explicit hiring announcements or management changes are cited post-2022 EIC funding round, the company’s rebranding from Genetika+ to NeuroKaire likely coincides with operational maturation ahead of commercialization.

The current team composition—spanning clinical neuroscience, product development, and business strategy—positions NeuroKaire to advance its AI-driven platform toward regulatory milestones and partnerships with healthcare providers. However, gaps remain in publicly available data regarding recent growth metrics or open positions.

Sources

• About Us | NeuroKaire
• NeuroKaire - Startup Nation Finder
• Genetika+ - PMWC Precision Medicine World Conference
• Cookie Policy | NeuroKaire
• Fava Slides.pptx - American Psychiatric Association

7 The Media Features and Publications

GenetikaPlus Ltd: Media Features, Publications, and Events

GenetikaPlus Ltd, now known as NeuroKaire, received the prestigious European Innovation Council (EIC) Accelerator funding in March 2022. This article explores the media features, publications, podcasts, and conference participations involving the company since then.

Media Features and Publications

GenetikaPlus, now NeuroKaire, has been featured in various publications focusing on its innovative approach to precision medicine in psychiatry and neurology. The company's platform combines stem cell technology, genomics, and AI to optimize drug treatment for patients. This approach has been highlighted in publications discussing advancements in personalized medicine for mental health conditions like depression.

Podcasts and Interviews

While specific podcasts directly featuring GenetikaPlus/NeuroKaire's team members could not be identified, the company's work aligns with broader discussions in genetics and precision medicine. Experts in related fields have participated in various science and health podcasts, but direct involvement from NeuroKaire team members in notable podcasts is not readily available.

Conference and Fair Visits

NeuroKaire has actively participated in several conferences, showcasing its innovative approach to precision medicine. Notable presentations include the CNS Summit 2024, where the company discussed using neuronal plasticity markers in iPSC-derived neurons for drug response models in Alzheimer’s Disease. Additionally, NeuroKaire presented at the AD/PD 2024 and the Psych Congress 2023, focusing on novel therapeutic approaches and precision medicine in depression.

Involvement in Events

NeuroKaire's involvement in events is marked by its participation in scientific conferences and its receipt of the EIC Accelerator funding. This funding has been instrumental in bringing its depression drug matching platform to market, aiming to improve treatment outcomes for major depressive disorder (MDD).

Conclusion

GenetikaPlus, now NeuroKaire, has been at the forefront of precision medicine in psychiatry and neurology. The company's innovative approach and participation in key scientific events have contributed significantly to advancements in personalized healthcare solutions.

Sources

• NeuroKaire Resources
• Transforming Psychiatry and Neurology Care | NeuroKaire
• Genetika+: Precision Medicine Solutions for Mental Health
• Genetika+: precision medicine solutions for mental health
• Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market